Dysregulated lipid metabolites GML and GMO were associated with cytotoxic T cell function and serve as biomarkers for acute pulmonary embolism - Scorecard - MDSpire
Advertisement
Dysregulated lipid metabolites GML and GMO were associated with cytotoxic T cell function and serve as biomarkers for acute pulmonary embolism
Clinical Scorecard: Altered lipid metabolites GML and GMO correlate with cytotoxic T cell activity and may act as biomarkers for acute pulmonary embolism
At a Glance
Category
Detail
Condition
Acute Pulmonary Embolism (APE)
Key Mechanisms
Elevated serum GML and GMO impair cytotoxic T cell function by downregulating Notch1 signaling and cytotoxic proteins.
Target Population
Patients with acute pulmonary embolism and related diseases.
Care Setting
Clinical diagnosis and management of acute pulmonary embolism.
Key Highlights
203 upregulated and 57 downregulated serum lipids identified in APE versus controls.
Significantly elevated serum GML and GMO levels in APE compared to healthy controls.
High sensitivity and specificity for GML and GMO as diagnostic biomarkers.
Cytotoxic T cells from APE patients exhibited decreased granzyme B, perforin, and granulysin.
GML and GMO reduced Notch1 and granzyme B expression in T cells in vitro.
Guideline-Based Recommendations
Diagnosis
Use clinical scoring tools combined with D-dimer testing for preliminary screening of APE.
Confirmatory imaging is necessary due to D-dimer's low specificity.
Management
Explore new non-invasive biomarkers for early diagnosis and severity assessment of APE.
Monitoring & Follow-up
Monitor serum levels of GML and GMO for correlation with disease severity.
Risks
High risk of misdiagnosis and delayed diagnosis in APE, with a 30-day mortality rate of 15%-30% in high-risk cases.
Patient & Prescribing Data
Patients diagnosed with acute pulmonary embolism.
Elevated GML and GMO may indicate the need for early intervention and personalized treatment.
Clinical Best Practices
Utilize comprehensive lipidomic analysis for biomarker discovery in APE.
Incorporate targeted metabolite analyses to validate lipid biomarkers.
